New drug aims to tame dangerous immune reactions from cancer therapy
NCT ID NCT05306080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether an investigational drug called Tadekinig alfa can safely and feasibly treat severe immune overreactions (CRS and HLH-like syndrome) that can occur after CAR T cell therapy. Ten adult participants who are already in a CAR T cell trial will receive injections of the drug. The goal is to see if this rescue therapy can help control these serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tadekinig alfa (IL-18BP)
What this could lead to
If successful, this could provide a safer way to manage dangerous side effects from CAR T cell therapy, making the treatment more tolerable.
What could go wrong
This is a very early, small pilot study with only 10 participants, so results may not apply broadly. The drug may not effectively control CRS or HLH-like syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HLH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••